Ironwood Pharma在CFO转型后倒闭

2026-05-13 23:22

Ironwood Pharmaceuticals (IRWD) lost ~12% on Wednesday after the bowel disease drugmaker announced the appointment of an interim chief financial officer following the resignation of its current CFO, Gregory Martini.
On Friday, Martini, who also served as a senior vice president of the company, announced his decision to resign effective May 15, the Boston, Massachusetts-based biotech said in a regulatory filing.
His resignation is not due to any dispute or any issue related to the company's financial reporting, according to the filing.
Ronald Silver, who has served as the company’s senior vice president, corporate controller, and chief accounting officer since January 2025, will succeed Martini on an interim basis following his resignation.
The departure comes days after Ironwood (IRWD) reaffirmed its full-year outlook alongside its Q1 2026 results, sending its shares sharply lower last week.

More on Ironwood Pharmaceuticals